Literature DB >> 30252536

RARβ acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells.

Ying Hu1, Samuel W French2, Thinh Chau1, Hui-Xin Liu1, Lili Sheng1, Fang Wei3, Jesse Stondell4, Juan C Garcia4, Yanlei Du3, Christopher L Bowlus4, Yu-Jui Yvonne Wan1.   

Abstract

This study investigates the mechanism and consequences of microRNA-22 ( miR-22) induction. Our data revealed for the first time that retinoic acid (RA) and histone deacetylase (HDAC) inhibitors, including short-chain fatty acids and suberanilohydroxamic acid (SAHA), could individually or in combination induce miR-22. This induction was mediated via RA receptor β (RARβ) binding to a direct repeat 5 (DR5) motif. In addition, we uncovered HDAC1 as a novel miR-22 target. In an miR-22-dependent manner, HDAC inhibitors and RA reduced HDAC1, HDAC4, and sirtuin 1 (SIRT1), which were involved in chromatin remodeling of the RARβ and nerve growth factor IB ( NUR77). Thus, HDAC inhibitors and RA-induced miR-22 resulted in simultaneous induction of cytoplasmic RARβ and NUR77, leading to apoptosis of colon cancer cells. In mice, miR-22 and its inducers inhibited the growth of xenograft colon cancer. Moreover, tumor size reduction was accompanied by elevated miR-22, NUR77, and RARβ and by reduced HDACs. In human colon polyps and adenocarcinomas, miR-22 and RARβ were consistently reduced, which was associated with elevated HDAC1, HDAC4, and SIRT1 in colon adenocarcinomas. Results from this study revealed a novel anticancer mechanism of RARβ via miR-22 induction to epigenetically regulate itself and NUR77, providing a promising cancer treatment modality using miR-22 and its inducers.-Hu, Y., French, S. W., Chau, T., Liu, H.-X., Sheng, L., Wei, F., Stondell, J., Garcia, J. C., Du, Y., Bowlus, C. L., Wan, Y.-J. Y. RARβ acts as both an upstream regulator and downstream effector of miR-22, which epigenetically regulates NUR77 to induce apoptosis of colon cancer cells.

Entities:  

Keywords:  butyrate; nuclear receptor; propionate; protein deacetylase; short-chain fatty acid

Mesh:

Substances:

Year:  2018        PMID: 30252536      PMCID: PMC6338632          DOI: 10.1096/fj.201801390R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  56 in total

1.  Bile acids regulate nuclear receptor (Nur77) expression and intracellular location to control proliferation and apoptosis.

Authors:  Ying Hu; Thinh Chau; Hui-Xin Liu; Degui Liao; Ryan Keane; Yuqiang Nie; Hui Yang; Yu-Jui Yvonne Wan
Journal:  Mol Cancer Res       Date:  2014-09-17       Impact factor: 5.852

2.  An estrogen receptor alpha suppressor, microRNA-22, is downregulated in estrogen receptor alpha-positive human breast cancer cell lines and clinical samples.

Authors:  Jianhua Xiong; Dianke Yu; Na Wei; Hanjiang Fu; Tianjing Cai; Yuanyu Huang; Chen Wu; Xiaofei Zheng; Quan Du; Dongxin Lin; Zicai Liang
Journal:  FEBS J       Date:  2010-02-17       Impact factor: 5.542

3.  Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut.

Authors:  Susan A Joyce; John MacSharry; Patrick G Casey; Michael Kinsella; Eileen F Murphy; Fergus Shanahan; Colin Hill; Cormac G M Gahan
Journal:  Proc Natl Acad Sci U S A       Date:  2014-05-05       Impact factor: 11.205

4.  Orphan receptor TR3 participates in cisplatin-induced apoptosis via Chk2 phosphorylation to repress intestinal tumorigenesis.

Authors:  Lu-ming Yao; Jian-ping He; Hang-zi Chen; Yuan Wang; Wei-jia Wang; Rong Wu; Chun-dong Yu; Qiao Wu
Journal:  Carcinogenesis       Date:  2011-12-09       Impact factor: 4.944

5.  MicroRNA-22 is induced by vitamin D and contributes to its antiproliferative, antimigratory and gene regulatory effects in colon cancer cells.

Authors:  Silvia Alvarez-Díaz; Noelia Valle; Gemma Ferrer-Mayorga; Luis Lombardía; Mercedes Herrera; Orlando Domínguez; Miguel F Segura; Félix Bonilla; Eva Hernando; Alberto Muñoz
Journal:  Hum Mol Genet       Date:  2012-02-10       Impact factor: 6.150

Review 6.  The vitamin D receptor in cancer.

Authors:  James Thorne; Moray J Campbell
Journal:  Proc Nutr Soc       Date:  2008-05       Impact factor: 6.297

7.  microRNA-22 downregulation of galectin-9 influences lymphocyte apoptosis and tumor cell proliferation in liver cancer.

Authors:  Qianqian Yang; Weichao Jiang; Chunbo Zhuang; Zhi Geng; Chen Hou; Da Huang; Lihua Hu; Xiaobei Wang
Journal:  Oncol Rep       Date:  2015-07-31       Impact factor: 3.906

8.  Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles.

Authors:  Marta Lionetti; Luca Agnelli; Laura Mosca; Sonia Fabris; Adrian Andronache; Katia Todoerti; Domenica Ronchetti; Giorgio Lambertenghi Deliliers; Antonino Neri
Journal:  Genes Chromosomes Cancer       Date:  2009-06       Impact factor: 5.006

Review 9.  Molecular mechanisms and clinical applications of miR-22 in regulating malignant progression in human cancer (Review).

Authors:  Jingyu Wang; Yuan Li; Meiman Ding; Honghe Zhang; Xiaoming Xu; Jinlong Tang
Journal:  Int J Oncol       Date:  2016-12-19       Impact factor: 5.650

Review 10.  Bile acid nuclear receptor FXR and digestive system diseases.

Authors:  Lili Ding; Li Yang; Zhengtao Wang; Wendong Huang
Journal:  Acta Pharm Sin B       Date:  2015-02-25       Impact factor: 11.413

View more
  8 in total

1.  Retinoic acid and microRNA.

Authors:  Lijun Wang; Atharva Piyush Rohatgi; Yu-Jui Yvonne Wan
Journal:  Methods Enzymol       Date:  2020-03-28       Impact factor: 1.600

2.  Hepatocellular carcinoma immunotherapy: The impact of epigenetic drugs and the gut microbiome.

Authors:  Farzam Vaziri; Steven Colquhoun; Yu-Jui Yvonne Wan
Journal:  Liver Res       Date:  2020-10-17

3.  Integrated Bioinformatics Analysis to Identify Abnormal Methylated Differentially Expressed Genes for Predicting Prognosis of Human Colon Cancer.

Authors:  Yanbo Luo; Fenglin Sun; Xiaowen Peng; Dong Dong; Wentao Ou; Yongke Xie; Yuqi Luo
Journal:  Int J Gen Med       Date:  2021-08-24

4.  Reposition of the anti-inflammatory drug diacerein in an in-vivo colorectal cancer model.

Authors:  Raghda T Abdel-Latif; Walaa Wadie; Yousra Abdel-Mottaleb; Dalaal M Abdallah; Nabila N El-Maraghy; Hanan S El-Abhar
Journal:  Saudi Pharm J       Date:  2021-12-31       Impact factor: 4.330

5.  MiR-22 Deficiency Fosters Hepatocellular Carcinoma Development in Fatty Liver.

Authors:  Monika Gjorgjieva; Anne-Sophie Ay; Marta Correia de Sousa; Etienne Delangre; Dobrochna Dolicka; Cyril Sobolewski; Christine Maeder; Margot Fournier; Christine Sempoux; Michelangelo Foti
Journal:  Cells       Date:  2022-09-14       Impact factor: 7.666

6.  miR-22 inhibition reduces hepatic steatosis via FGF21 and FGFR1 induction.

Authors:  Ying Hu; Hui-Xin Liu; Prasant Kuma Jena; Lili Sheng; Mohamed R Ali; Yu-Jui Yvonne Wan
Journal:  JHEP Rep       Date:  2020-02-18

7.  MiR-22 as a metabolic silencer and liver tumor suppressor.

Authors:  Lijun Wang; Yu-Shiuan Wang; Eko Mugiyanto; Wei-Chiao Chang; Yu-Jui Yvonne Wan
Journal:  Liver Res       Date:  2020-06-09

8.  GeromiRs Are Downregulated in the Tumor Microenvironment during Colon Cancer Colonization of the Liver in a Murine Metastasis Model.

Authors:  Daniela Gerovska; Patricia Garcia-Gallastegi; Olatz Crende; Joana Márquez; Gorka Larrinaga; Maite Unzurrunzaga; Marcos J Araúzo-Bravo; Iker Badiola
Journal:  Int J Mol Sci       Date:  2021-05-01       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.